Cargando…
Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases
B-cell targeted therapies (BCTT) are now widely used in autoimmune rheumatic diseases, including SLE, antineutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis. Early studies suggested that rituximab did not influence serum immunoglobulins. However, subsequently, with increa...
Autores principales: | Wijetilleka, Sonali, Jayne, David, Mukhtyar, Chetan, Karim, Mohammed Yousuf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667775/ https://www.ncbi.nlm.nih.gov/pubmed/31413852 http://dx.doi.org/10.1136/lupus-2019-000337 |
Ejemplares similares
-
Peri-areolar double-pedicle technique in the treatment of iatrogenic gynecomastia
por: Cannistrà, Claudio, et al.
Publicado: (2021) -
Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease
por: Shenoy, Padmanabha, et al.
Publicado: (2021) -
Antiretinal antibody- proven autoimmune retinopathy
por: Abraham, Sharanya, et al.
Publicado: (2017) -
B‐cell very late antigen‐4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity
por: Lehmann‐Horn, Klaus, et al.
Publicado: (2015) -
Management of Iatrogenic Pulmonary Artery Injury during Pulmonary Artery Banding
por: Makhija, Neeti, et al.
Publicado: (2017)